PepGen shares surged 119.55% after announcing an underwritten public offering, with proceeds to support clinical trials for neuromuscular diseases.
PepGen shares surged 119.55% after announcing an underwritten public offering, with proceeds to support clinical trials for neuromuscular diseases.